Press release BoxID: 550660 (BIOTRONIK)
  • Woermannkehre 1
  • 12359 Berlin
  • Contact person
  • Jacqueline Bernhardt
  • +49 (30) 68905-1401

BIOTRONIK Announces Positive Results for Pantera Lux Paclitaxel Releasing Balloon in both Diabetic and Non diabetic Subgroups

(PresseBox) (BUELACH, Switzerland,, ) Twelve month results from the DELUX registry demonstrating excellent safety and efficacy for the Pantera Lux Paclitaxel Releasing Balloon in 1,064 patients were presented by Professor Gert Richardt, MD, Segeberger Heart Center Clinic, Germany, and Christoph K. Naber, MD, Elisabeth Hospital, Germany, at the "Transcatheter Cardiovascular Therapeutics" congress (TCT 2012) in Miami last week.

The registry enrolled a population of mostly in-stent restenotic patients (86.3%) who had a very low major adverse cardiac event (MACE) rate of 13.7% and a revascularization rate of 5.0%. A further analysis of the diabetic subgroup of 363 patients showed similarly low revascularization rates of 6.2%.

"The use of drug eluting balloons in difficult to treat lesions - as documented in the DELUX registry - can result in a substantial benefit for patients with limited further treatment options. This 12-month clinical endpoint provides us useful insight into their mid-term outcomes and more confidence selecting the right patient and lesion for this exciting new therapy option," remarked Professor Richardt.

The Pantera Lux Paclitaxel Releasing Balloon is a novel treatment for restenotic coronary artery lesions after drug-eluting or bare metal stenting. The device is based on the highly deliverable Pantera semi compliant balloon, which is then coated with a matrix of proven antiproliferative paclitaxel and the biocompatible butyryl-tri-hexyl citrate (BTHC) excipient and enables an optimal drug transfer to the target lesion tissue.

DELUX is a prospective, multicenter, international registry evaluating the Pantera Lux Paclitaxel Releasing Balloon in 1064 patients in a real-world setting. The primary endpoint was the 6-month cumulative MACE rate defined as a composite of all death, nonfatal myocardial infarction and clinically driven target vessel revascularization. Major secondary outcomes are cumulative MACE rates at 1 and 12 months.

Alain Aimonetti, Vice President of Sales and Marketing, BIOTRONIK Vascular Intervention, commented, "The positive results reinforce our commitment at BIOTRONIK to expand investments into the drug eluting balloon therapy. We are currently exploring further indications such as coronary bifurcations and below the knee lesions with our broad Lux clinical program."


As one of the world's leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success-and deliver confidence and peace of mind to physicians and their patients worldwide.

More information: